Wells Fargo lowered the firm’s price target on NeuroPace (NPCE) to $13 from $15 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenues well ahead of Wells’ and consensus estimates. Management increased revenue guidance for the year again, but held the line on OpEx andGM guidance, the firm adds.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter